Overview
Doug Wentzel focuses his practice on patent and trade secret litigation. Doug successfully represents clients in district courts across the country and before the International Trade Commission (ITC), Patent Trial and Appeal Board (PTAB), and Patent Office. Doug is adept at understanding complex technologies and has assisted clients in cases covering a broad spectrum of technologies, including wearable health devices, minimally invasive heart repair devices, respiratory therapy products, automotive shock absorbers, microdermabrasion systems, and more. Doug also has experience litigating design patents.
Among other client successes, Doug played an integral role in a high-profile ITC investigation resulting in an import ban of the Apple Watch, and in persuading both the PTAB and the Patent Office not to institute challenges to the patents underlying the import ban.
Doug is actively involved in the legal community and is a co-chair of the Young Lawyers Division of the Federal Bar Association’s Orange County Chapter.
Education
- University of Pennsylvania Law School (J.D., 2016), cum laude
- Drexel University (B.S. Civil Engineering, 2013), summa cum laude
Recognition
Awards & Honors
- Recognized as a Rising Star in IP by Managing IP, 2023 & 2024
Affiliations
- Federal Bar Association – Orange County Chapter
- Co-Chair, Young Lawyers Division
- Association of Business Trial Lawyers – Orange County
- Orange County Bar Association
News & Insights
Articles
Co-author, “35 U.S.C. § 325(d) Petition Practice in Ex Parte Reexaminations,” Reuters Westlaw, October 2024.
Co-author, “Tips for Patent Prosecutors from Litigators: Enhancing Litigation Outcomes,” IP Watchdog, August 2024.
Journal Articles
- Stays Pending Inter Partes Review: Not in the Eastern District of Texas, 98 J. Pat. & Trademark Off. Soc’y 120 (2016)
- Uber & Alice: Could One Patent Really Take Down this Ridesharing Giant?, 98 J. Pat. & Trademark Off. Soc’y 86 (2016)
Editor and Contributor, KnobbeMedical.com Blog
- AI & the FDA
- Developments in Patent Disputes Between Apple and Alivecor
- Apple Watch Found to Infringe AliveCor ECG Patents
- Medical device innovations and IP: A strategy is everything.
- BioNTech to Ship Modular mRNA Vaccine Factory to Rwanda
- AI and Cancer Diagnostics
- Federal Circuit Reverses District Court’s Decision Based on On-Sale Bar (Junker v. Medical Components, Inc.)
- FDA Seeks $7.2 Billion Budget for 2024
- FDA: Approval for Novel Medical Devices Remains a High Priority, Despite COVID-19
- FDA Breakthrough Device Designation for Biology-Guided Radiotherapy (‘BgRT’) Device
- Alpha Tau Receives FDA Breakthrough Device Designation for Alpha DaRT Treatment of GBM
- Medical Device Trade Secret Not Publicly Disclosed via Patenting, Displaying, and Selling Covered Product, 7th Cir. Affirms
- FDA Taking Steps to Prevent Future Medical Device Shortages
- Boston Scientific To Acquire Blood Clot Removal Tech Company Devoro Medical
- Stryker to Acquire Surgical Smoke Evacuator Company SafeAir
- Materialise Receives First-Ever 510(k) Clearance for Anatomical Model 3D Printing Software
- FDA Issues Final Guidance on Software as a Medical Device
- Testing of Jenex TherOZap™ Device Set to Begin
Editor and Contributor, Knobbe Martens Litigation Blog
- A Patent Must Describe What Is Claimed, Not What Infringes
- “Quotation” Letter Found to Constitute Offer Invalidating Patents
- Resolving Claim Construction Dispute at 12(b)(6) Stage May Be Error if Specification Indicates Claim Term Does Not Have its Plain Meaning
- Combining Abstract Ideas Does Not Make Them Less Abstract
- An Expert Witness Need Not Have Been a Posita at the Time of the Invention
- Skinny Labeling May Not Be Enough to Avoid Induced Infringement Allegations
- Unclean Hands and Inequitable Conduct: Dishonesty Is Not the Best Policy
- Claimed Ranges Overlapping the Prior Art Can Lead To Short Patent Shelf-Life
- Exhibit Combustion: Disavowing Contradictory Statements Contained in Complaint Exhibits
- The Patent Ineligibility of Digital Imaging Processing Method Claims
- Incorporation by Reference: Patent Portfolio Builder or Destroyer?
- “Filtering” Appropriate Claim Construction Reasoning
- In Re Oath Holdings Inc.
- Result-Oriented Claims Based on Natural Laws Held Invalid Under § 101